title: Ixekizumab for psoriasis--Authors' reply.
authors: Dermatology Centre, Salford Royal Hospital, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK. Electronic address: christopher.griffiths@manchester.ac.uk.
authors: Christopher E M
authors: CE
authors: Griffiths
authors: Probity Medical Research, Waterloo, ON, Canada.
authors: Kim A
authors: KA
authors: Papp
authors: Eli Lilly & Co, Indianapolis, IN, USA.
authors: Susan G
authors: SG
authors: Ball
authors: Eli Lilly & Co, Indianapolis, IN, USA.
authors: Brian J
authors: BJ
authors: Nickoloff
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor